Ringkasan AI
We reviewed 32 live results for tofacitinib citrate and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Medicine and Pharmaceutical.
We reviewed 32 live results for tofacitinib citrate and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Medicine and Pharmaceutical.
Sumber: Lucius Pharmaceuticals (Lao) Co., Ltd.
Deskripsi
LuciTofa is an oral medication containing 5mg of Tofacitinib, a Janus kinase (JAK) inhibitor used to treat chronic inflammatory and autoimmune conditions. It is specifically indicated for adult patients suffering from moderately to severely active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ulcerative Colitis (UC). This prescription medicine is often utilized when traditional therapies like methotrexate have proven inadequate. As a brand-name generic, it provides a therapeutic alternative for managing joint pain, swelling, and bowel inflammation associated with these conditions.
Paling cocok untuk
Rheumatoid Arthritis management, Psoriatic Arthritis relief, Ulcerative Colitis treatment and Patients non-responsive to methotrexate
Penilaian
Sumber: Taj Pharma
Deskripsi
Generic tofacitinib 5mg tablets produced in WHO-GMP certified facilities. These tablets are used for the treatment of various autoimmune diseases and are exported to international markets as a cost-effective alternative to the original brand.
Paling cocok untuk
cost-conscious patients, export markets and generic medicine seekers
Penilaian
Sumber: Bumrungrad International Hospital
Deskripsi
An oral targeted synthetic DMARD (tsDMARD) that acts as a JAK inhibitor. It provides an alternative to injectable biologics for patients who have not successfully responded to first-line conventional synthetic DMARDs.
Paling cocok untuk
JAK inhibitor therapy, oral arthritis medication, targeted synthetic DMARDs and private hospital rheumatology
Penilaian
| Bandingkan | LuciTofa (Tofacitinib 5mg) | Taj Pharma Tofacitinib Tablets 5mg | Tofacitinib |
|---|---|---|---|
| Sumber | Lucius Pharmaceuticals (Lao) Co., Ltd. | Taj Pharma | Bumrungrad International Hospital |
| Deskripsi | LuciTofa is an oral medication containing 5mg of Tofacitinib, a Janus kinase (JAK) inhibitor used to treat chronic inflammatory and autoimmune conditions. It is specifically indicated for adult patients suffering from moderately to severely active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ulcerative Colitis (UC). This prescription medicine is often utilized when traditional therapies like methotrexate have proven inadequate. As a brand-name generic, it provides a therapeutic alternative for managing joint pain, swelling, and bowel inflammation associated with these conditions. | Generic tofacitinib 5mg tablets produced in WHO-GMP certified facilities. These tablets are used for the treatment of various autoimmune diseases and are exported to international markets as a cost-effective alternative to the original brand. | An oral targeted synthetic DMARD (tsDMARD) that acts as a JAK inhibitor. It provides an alternative to injectable biologics for patients who have not successfully responded to first-line conventional synthetic DMARDs. |
| Paling cocok untuk | Rheumatoid Arthritis management, Psoriatic Arthritis relief, Ulcerative Colitis treatment and Patients non-responsive to methotrexate | cost-conscious patients, export markets and generic medicine seekers | JAK inhibitor therapy, oral arthritis medication, targeted synthetic DMARDs and private hospital rheumatology |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"LuciTofa (Tofacitinib 5mg) from Lucius Pharmaceuticals (Lao) Co., Ltd.."
Saya memilih ini karena LuciTofa is a recognized generic version of Tofacitinib with a documented distribution presence in Thailand, offering a treatment option for patients with autoimmune conditions who require JAK inhibitor therapy.